-
-
-
-
-
-
-
Opus Genetics sets September timeline for OPGx-BEST1 trial data
-
-
-
-
-
-
-
Opus Genetics (IRD) Reiterated at Market Outperform by Citizens After Investor Meet
-
-
-
-
-
-
-
Citizens Starts Opus Genetics (IRD) at Market Outperform
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Opus Genetics (IRD)
-
-
-
-
-
-
-
Brookline Capital Markets Starts Opus Genetics (IRD) at Buy
-
-
-
-
-
-
-
Opus Genetics, Inc. (IRD) Tops Q2 EPS by 7c
-
-
-
-
-
-
-
Opus Genetics (IRD) Granted FDA RMAT Designation for OPGx-LCA5 Gene Therapy Candidate
-
456,578 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

